Ratings Inventiva

Equities

IVA

FR0013233012

Market Closed - Euronext Paris Other stock markets 11:35:06 2024-05-09 am EDT			Pre-market 02:00:16 am
3.195 ^EUR	-1.99%		3.198	+0.09%

Apr. 22	Inventiva: UBS Group falls below 5% threshold	CF
Apr. 18	Transcript : Inventiva S.A. - Special Call

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
INVENTIVA	-21.98%	179M	-
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B	B+
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B	B+
ARGENX SE	+1.57%	22.33B	B
BIONTECH SE	-12.77%	22.19B	B+
GENMAB A/S	-7.05%	18.69B	A-
WUXI APPTEC CO., LTD.	-37.64%	17.74B	A-
BEIGENE, LTD.	-6.50%	17.64B	B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	14.05B	C+
SAREPTA THERAPEUTICS, INC.	+37.20%	12.51B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes